Oncolytic Viral Immunochemotherapy in Patients With Ovarian Cancer
JAMA Oncology Author Interviews
00:00
Allewick-Prime Immunotherapy in a Phase 2 Study
Allewick induced favorable systemic and intratumural immune activities. The patients were heavily pre-treated with a median of four prior treatments, some up to nine. So the paradigm here is using immunotherapy to affect response.
Play episode from 04:31
Transcript
